“This collaboration with Jubilant Therapeutics will further advance our comprehensive research efforts to find therapeutics to diminish cytokine storms and decrease COVID-19 symptom gravity,” said Yulia Nefedova.
Jan 16, 2021
Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure the continuity of promising clinical development programs of potential future strategic interest to Pfizer.
Jan 13, 2021
“Today’s authorisation is a really important milestone towards enabling children to have access to age-appropriate formulations of HIV medicine," said Deborah Waterhouse, CEO of ViiV Healthcare
Jan 13, 2021
Vir Biotechnology, Inc. and GlaxoSmithKline plc today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in Phase 1b/2a clinical trial
Jan 12, 2021
Merck announced the U.S. FDA accepted for priority review a Biologics License Application for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease.
Jan 12, 2021
The application includes data for a new, 50 mg tablet that can be dispersed in water and which was developed to facilitate use in children, who are disproportionately affected by the disease.
Jan 08, 2021
AstraZeneca’s COVID-19 vaccine has been granted emergency use authorization in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunization of adults.
Jan 07, 2021
Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin hydrochloride is appropriate.
Jan 07, 2021
“The EMA’s decision to validate our application represents important progress for the esophageal cancer community, and we look forward to potentially bringing Opdivo to patients in the EU who may benefit.”
Jan 05, 2021
Pfizer inc. and OPKO Health Inc. announced today that the USFDA has accepted for filing the initial Biologics License Application for somatrogon, a long-acting human growth hormone for the treatment of pediatric patients with growth hormone deficiency.
Jan 05, 2021
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms
Jan 02, 2021
LORBRENA is a third-generation ALK inhibitor specifically developed to inhibit the most common tumour mutations that drive resistance to current medications and to address brain metastases
Dec 29, 2020
“With these 100 million additional doses, the United States will be able to protect more individuals and hopefully end this devastating pandemic more quickly,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
Dec 24, 2020
“Glioblastoma is an aggressive cancer with a very poor prognosis that has seen limited new treatment options over the last 15 years,” said Michael Mandola, Ph.D., Oncology Development Program Lead, Bristol Myers Squibb.
Dec 23, 2020
“We are excited to partner with Menarini for Ryaltris™ across Europe as they have a proven track record in partnering and commercializing respiratory products in the region, " said Achin Gupta, Executive Vice President, Business Head EMEA-L, Glenmark Pharmaceuticals
Dec 23, 2020
"Building upon the promising clinical findings to date for MK-7110, Merck is pleased to be collaborating with the U.S. Government to advance the manufacture and distribution of this candidate for patients with serious COVID-19 disease," said Dr. Roger M. Perlmutter, president, Merck Research Lab.
Dec 23, 2020
This authorization represents the first time people living with HIV in Europe may be able to receive a long-acting injectable treatment that removes the need to take daily oral tablets
Dec 21, 2020
BENLYSTA is the first medicine approved to treat systemic lupus and adults with active lupus nephritis, an important treatment advance for patients with this incurable autoimmune disease.
Dec 18, 2020
This new dosing option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer and once approved, will be available to patients with locally advanced, unresectable NSCLC weighing more than 30kg.
Dec 15, 2020
Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication
Dec 12, 2020
“Patients in Europe with MSI-H/dMMR colorectal cancer have had only chemotherapy-containing regimens available to them in the first-line treatment setting and have historically faced poor outcomes,” said Dr. Vicki Goodman.
Dec 11, 2020
The FDA’s acceptance of our application for 20vPnC is yet another significant milestone in Pfizer’s continuing efforts to help protect adults against pneumococcal disease,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research and Development, Pfizer.
Dec 09, 2020
"We believe JBI-802 could one day serve as a powerful therapeutic agent for the treatment of specific cancers, including myelodysplastic syndrome, select acute myeloid leukemia and solid tumor subsets.”
Dec 08, 2020
We continue to be encouraged by the findings from this Phase 1/2 study, which now include durable factor VIII expression through one year of follow-up, and we look forward to continuing to follow these patients
Dec 07, 2020
PureTech’s global, randomized, double-blind, placebo-controlled Phase 2 trial is designed to evaluate the efficacy, safety and tolerability of LYT-100 in adults with post-acute COVID-19 respiratory complications
Dec 05, 2020
The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research
Dec 01, 2020
Objective of the study is to assess the efficacy of Carragelose nasal and throat spray in reducing the rate, severity, and duration of COVID-19 infections
Dec 01, 2020
Atopic dermatitis is a chronic inflammatory disease of the skin that can be debilitating, and severe disease can significantly impact many aspects of life for both children and their families.
Nov 30, 2020
Hon'ble Prime Minister's leadership vision, in-depth understanding and knowledge of the facts guided us in facilitating the interactions and discussions on the vaccines and therapeutics for COVID-19
Nov 30, 2020
Senhwa announces multiple IND application submissions to US FDA and Health Canada evaluating its investigational drug, CX-5461, for the treatment of patients with solid tumours with BRCA2 or PALB2 mutations
Nov 26, 2020
DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top-ranked companies in terms of Corporate Sustainability within each industry featured in the index.
Nov 26, 2020
Piramal Sarvajal, the safe drinking water initiative of Piramal Foundation launched a tool named Composite Water Vulnerability Index at its recent Webinar on ‘Sustainable Water Security for Urban Under-Served’.
Nov 25, 2020
The vaccine's clinical study not only provides key data for the launch of the vaccine in China, but also may play a positive role in the widespread promotion and use of the vaccine throughout Asia and around the world
Nov 25, 2020
The oral antiviral medication Favipiravir, which prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with mild to moderate COVID-19.
Nov 23, 2020
“The results from the CROWN trial demonstrate that LORBRENA has the potential to be a practice-changing, first-line option, and we thank the many people and their families who participated in this trial.”
Nov 19, 2020
The approval was based on the results of Phase III and Phase II clinical studies conducted globally to evaluate Fycompa as an adjunctive therapy in pediatric patients with POS or PGTCS
Nov 16, 2020
This initiative supports pharmaceutical companies by providing them for free with the necessary tools to protect COVID-19 relevant medicines and vaccines against counterfeiting
Nov 13, 2020
AstraZeneca and Amgen today announced positive results from the new medicine tezepelumab in patients with severe, uncontrolled asthma.
Nov 10, 2020
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla
Nov 09, 2020
Dr. Reddy’s announced its partnership with Biotechnology Industry Research Assistance Council, Department of Biotechnology, Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.
Oct 29, 2020
The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Mutations in OTOF lead to severe or profound congenital hearing loss
Oct 28, 2020
This spray has been tested and proven for efficacy as well as fast action on the Covid19 virus by an independent accredited US-based lab.
Oct 27, 2020
“Atopic dermatitis is a serious, unpredictable, and often debilitating condition that can have a significant impact on the daily lives of patients and their families,” said Michael Corbo.
Oct 27, 2020
ViiV Healthcare, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme.
Oct 21, 2020
Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine
Oct 21, 2020
A pivotal Phase 3 trial of Dupixent met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma
Oct 13, 2020
Novellus Therapeutics exclusively licenses induced mesenchymal stem cells (iMSCs) to NoveCite for COVID-19 related acute respiratory distress syndrome (ARDS) and other acute respiratory conditions
Oct 13, 2020
The initiation of the pivotal Phase 3 dosing study of giroctocogene fitelparvovec is a significant achievement for Pfizer as we continue our longstanding commitment to improving care for the hemophilia community
Oct 07, 2020
Positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) were shared in a presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Sep 21, 2020
Sanofi and GSK finalised and signed today an advanced purchase agreement with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine, once the vaccine is approved.
Sep 18, 2020
Sunday, January 17, 2021